fbpx

Atara Biotherapeutics

Pipeline

ATA3219

ATA3219: Developing Off-the-Shelf Allogeneic CD19 Program for B-Cell Malignancies, With IND Expected in Q4 2022

  • Academic program generated proof of principle for EBV T-cell platform potential to generate off-the-shelf, allogeneic CAR T immunotherapies
  • ATA3219: Next-generation off-the-shelf, allogeneic CD19-1XX CAR+ EBV T-cell immunotherapy containing a modified CD3ζ signaling domain, 1XX.

Curran KJ, Sauter CS, Kernan NA, et al. Durable remission following “Off‐the‐Shelf” Chimeric Antigen Receptor (CAR) T‐cells in patients with relapse/refractory (R/R) B‐cell malignancies. Biol Blood Marrow Transplant. 2020;26(3):S89.
IND = Investigational New Drug

ATA3219

Program/Indication Preclinical Phase 1 Phase 2 Phase 3
ATA3219: B-cell malignancies
  • Target: CD19
  • Technologies: Novel CAR T 1XX co-stimulation
  • Off-the-shelf, allogeneic
Program/Indication Phase
ATA3219: B-cell malignancies Preclinical
  • Target: CD19
  • Technologies: Novel CAR T 1XX co-stimulation
  • Off-the-shelf, allogeneic
Program/Indication
ATA3219: B-cell malignancies
Phase
Preclinical
  • Target: CD19
  • Technologies: Novel CAR T 1XX co-stimulation
  • Off-the-shelf, allogeneic

Next-Generation CAR T Technology

Our preclinical pipeline is rapidly expanding with novel technologies and next-generation, multi-targeted CAR T immunotherapies thanks to our collaborations with Moffitt Cancer Center and Memorial Sloan Kettering Cancer Center.
View Next-Generation CAR T

Patients

At Atara, we recognize that some patients with serious, life-threatening diseases may not have access to some clinical studies or satisfactory treatment alternatives. That is why we are committed to making every effort to support patients in need of treatment options.

View Patients

Medical Professionals

We have designed our clinical studies to evaluate the potential of our investigational treatments in a well-defined cohort of patients with eligibility criteria that allow for appropriate assessment of safety and clinical effect. If you are interested in learning more about our ongoing clinical studies, please contact us at ClinicalStudies@atarabio.com.

View Medical Professionals